Cell Pathways preclinical data

The Denver company presented evidence that its drug might inhibit tumors without incurring the gastrointestinal irritation typical of NSAIDs.

Studies in a colon cancer model in mice showed FGN-1 does not act on prostaglandins, and does not generally decrease turnover of the colon mucosa. Instead, there is some specific effect on cell division within the colon mucosa, which the company has yet to fully unravel. ...